DATABASE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

IVA — Inventiva S.A.

IVA (Inventiva S.A.) stock: $3.54, $835.3M market cap, $227.5M cash, $670.2M EV, $1.42B fully diluted market cap. Next expected readout: Sep-27. Lead program: IVA337 (NASH - Nonalcoholic Steatohepatitis), Phase 3. Data from Fully Diluted's biotech stocks database.

Share price
$3.54
Market cap
$835.3M
Cash
$227.5M
Enterprise value
$670.2M

Balance sheet

Cash$227.5M
Debt$62.4M
Net cash$165.1M
Enterprise value$670.2M
Basic shares236.0M shares
Fully diluted shares401.0M shares
Fully diluted market cap$1,419.4M
Cash per share$0.96

Cash figures as of 2026-06-05. Database snapshot: 2026-09-22.

Price history

Loading IVA daily closes…

Loading price history…

Upcoming catalysts

ExpectedDrugPhaseIndicationMgmt guide
Nov 11 - Dec 23IVA337Phase 3NASH - Nonalcoholic Steatohepatitis

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.
Subscribe to Compounding Ego